These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Bioterror and "bioart"--a plague o' both your houses. Annas GJ N Engl J Med; 2006 Jun; 354(25):2715-20. PubMed ID: 16790708 [No Abstract] [Full Text] [Related]
47. Too small to overlook. Maynard A; Rejeski D Nature; 2009 Jul; 460(7252):174. PubMed ID: 19587746 [No Abstract] [Full Text] [Related]
48. Regulation of biotechnology by executive orders: questions about constitutionality, legality and overall fairness to the American public. Cuomo P J Biolaw Bus; 2005; 8(2):30-42. PubMed ID: 16538813 [TBL] [Abstract][Full Text] [Related]
49. Nanotechnology and the U.S. Food and Drug Administration. Marlowe DE Stand News; 2005 Jul; 33(7):29-31. PubMed ID: 16237872 [No Abstract] [Full Text] [Related]
50. US animal biotech regulations "may not be adequate". Fox JL Nat Biotechnol; 2002 Oct; 20(10):959. PubMed ID: 12355099 [No Abstract] [Full Text] [Related]
51. Nanotechnology: using co-regulation to bring regulation of modern technologies into the 21st century. Reese M Health Matrix Clevel; 2013; 23(2):537-72. PubMed ID: 24341081 [No Abstract] [Full Text] [Related]
52. The long and winding road from Asilomar to Brussels: science, politics and the public in biotechnology and regulation. Abels G Sci Cult (Lond); 2005 Dec; 14(4):339-53. PubMed ID: 16619469 [No Abstract] [Full Text] [Related]
53. Commentary: Oversight of engineered nanomaterials in the workplace. Maynard AD J Law Med Ethics; 2009; 37(4):651-8. PubMed ID: 20122107 [TBL] [Abstract][Full Text] [Related]
57. Reflections on the year. Neale M Med Device Technol; 2001 Dec; 12(10):28-9. PubMed ID: 15966142 [No Abstract] [Full Text] [Related]
58. Gaps, inexperience, inconsistencies, and overlaps: crisis in the regulation of genetically modified plants and animals. Mandal GN William Mary Law Rev; 2004 Apr; 45(5):2167-259. PubMed ID: 16329219 [TBL] [Abstract][Full Text] [Related]
59. Risk factors: Nanomaterials should be defined. Stamm H Nature; 2011 Aug; 476(7361):399. PubMed ID: 21866144 [No Abstract] [Full Text] [Related]
60. Beyond biotechnology: FDA regulation of nanomedicine. Miller J Columbia Sci Technol Law Rev; 2003; 4():E5. PubMed ID: 15977335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]